What Is The Effect Of Alzheimer’s Disease On Eye And Can Ocular Changes Be Used As Biomarker For Alzheimer’s Disease?
Funder
National Health and Medical Research Council
Funding Amount
$718,002.00
Summary
Visual symptoms are frequent early complaints in Alzheimer’s (AD) patients. Examining eyes can be a simple, specific and inexpensive way to assess and diagnose AD and fill in an urgent need for a viable biomarker. Retina is unique part of central nervous system that can be imaged non-invasively and thus serves as a ‘window to the brain”. Monitoring the eyes will also help prevent negative effects of AD on vision by way of timely intervention, in addition to providing mechanistic insights in AD.
Early Detection Of Alzheimer's Disease Using Ocular Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$602,502.00
Summary
Curcumin fluorescence imaging of the retina will be tested for quantification of retinal amyloid plaque burden and rate of change. This will be compared to AD disease status, brain plaque burden and other markers to evaluate retinal imaging as an early test for AD.